The FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) study, a cardiovascular outcome trial for evolocumab, enrolled 27,564 patients with ASCVD and plasma LDL-C levels ≥70 mg/dL who had previously been treated with statins. The gene discussed is PCSK9; the disease is atherosclerosis.